X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4-Chlorokynurenine,Probenecid
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: VistaGen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 27, 2020
Details:
Under this agreement, VistaGen and Nuformix initially will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine,LSD
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Details:
The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
